COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics

COMPASS Pathways PLC ADR (CMPS): $12.21

0.77 (+6.73%)

POWR Rating

Component Grades













CMPS Stock Price Chart Interactive Chart >

Price chart for CMPS

CMPS Price/Volume Stats

Current price $12.21 52-week high $49.51
Prev. close $11.44 52-week low $6.54
Day low $11.40 Volume 342,400
Day high $12.28 Avg. volume 314,638
50-day MA $9.34 Dividend yield N/A
200-day MA $19.51 Market Cap 519.06M

COMPASS Pathways PLC ADR (CMPS) Company Bio

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.

CMPS Latest News Stream

Event/Time News Detail
Loading, please wait...

CMPS Latest Social Stream

Loading social stream, please wait...

View Full CMPS Social Stream

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS Pathways plc that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

COMPASS Pathways plc 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by COMPASS Pathways plc in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportPositive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRDLaunch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder

Yahoo | February 24, 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

GlobeNewswire | February 17, 2022

Why the Stock Market Is a Terrible Thermometer of Biotech Success

In this Backstage Pass segment, recorded on Feb. 4, Motley Fool contributor Rachel Warren discusses the psychedelic therapeutics market with Tim Schlidt, co-founder and partner at Palo Santo, a psychedelic investment fund. Schlidt explains that clinical milestones are the best way to gauge the health of this market going forward. Rachel Warren: What is one thing that we can all be watching to gauge the health of the psychedelic therapeutics market going forward?

Yahoo | February 17, 2022

Magic Mushroom''s Active Compound Could Relieve Depression For Up To One Year, New Study Finds

A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of major depression. In a new study, 58% of participants with major depressive disorder were in remission after one year of doing two sessions with psilocybin. “Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” said Roland Griffiths , Ph.D., Professor in Neuropsychopharmacology of Consciousness at Johns Hopkins School of Medicine. Psilocybin, also known as the active compound in “magic mushrooms,” is one of the compounds spearheading a pipeline that looks to advance psychedelic drugs for medical use. There are currently dozens of biotec...

Benzinga | February 16, 2022

Read More 'CMPS' Stories Here

CMPS Price Returns

1-mo 25.23%
3-mo -2.32%
6-mo -35.29%
1-year -64.65%
3-year N/A
5-year N/A
YTD -44.75%
2021 -53.61%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4748 seconds.